Preoperative evaluation and comprehensive risk assessment for children with Down syndrome
Corresponding Author
Amy Feldman Lewanda
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Correspondence
Amy Feldman Lewanda, Division of Genetics & Metabolism, Children's National Health System, 111 Michigan Ave. NW, Washington, DC 20010, USA
Email: [email protected]
Search for more papers by this authorAndrew Matisoff
Divisions of Anesthesiology, Sedation, and Perioperative Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorMary Revenis
Division of Neonatology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorAshraf Harahsheh
Division of Cardiology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorCraig Futterman
Division of Critical Care Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorGustavo Nino
Divisions of Pulmonary Medicine and Sleep Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorJay Greenberg
Divisions of Hematology and Oncology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorJohn S. Myseros
Division of Neurosurgery, Children's National Health System, Washington, DC, USA
Search for more papers by this authorKenneth N. Rosenbaum
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Search for more papers by this authorMarshall Summar
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Search for more papers by this authorCorresponding Author
Amy Feldman Lewanda
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Correspondence
Amy Feldman Lewanda, Division of Genetics & Metabolism, Children's National Health System, 111 Michigan Ave. NW, Washington, DC 20010, USA
Email: [email protected]
Search for more papers by this authorAndrew Matisoff
Divisions of Anesthesiology, Sedation, and Perioperative Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorMary Revenis
Division of Neonatology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorAshraf Harahsheh
Division of Cardiology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorCraig Futterman
Division of Critical Care Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorGustavo Nino
Divisions of Pulmonary Medicine and Sleep Medicine, Children's National Health System, Washington, DC, USA
Search for more papers by this authorJay Greenberg
Divisions of Hematology and Oncology, Children's National Health System, Washington, DC, USA
Search for more papers by this authorJohn S. Myseros
Division of Neurosurgery, Children's National Health System, Washington, DC, USA
Search for more papers by this authorKenneth N. Rosenbaum
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Search for more papers by this authorMarshall Summar
Division of Genetics & Metabolism, Children's National Health System, Washington, DC, USA
Search for more papers by this authorSummary
Down syndrome is a common chromosome disorder affecting all body systems. This creates unique physiologic concerns that can affect safety during anesthesia and surgery. Little consensus exists, however, on the best way to evaluate children with Down syndrome in preparation for surgery. We review a number of salient topics affecting these children in the perioperative period, including cervical spine instability, cardiovascular abnormalities, pulmonary hypertension, upper airway obstruction, hematologic disturbances, prematurity, low birth weight, and the use of supplements and alternative therapies. Recommendations include obtaining a complete blood count to detect an increased risk for bleeding or stroke, and cardiology evaluation to identify patients with pulmonary hypertension, as well as undiagnosed or residual heart disease. Pediatric cardiac anesthesiologists and intensivists should be involved as needed. The potential for cervical spine instability should be considered, and the anesthesiologist may wish to have several options available both for the medications and equipment used. The child's family should always be asked if he or she is on any nutritional supplements, as some products marketed to families may have secondary effects such as inhibition of platelet function. Using this evaluation in presurgical planning will allow physicians to better consider the individual circumstances for their patients with Down syndrome. Our goal was to optimize patient safety by choosing the most appropriate setting and perioperative personnel, and to mitigate those risk factors amenable to intervention.
References
- 1Sherman SL, Allen EG, Bean LH et al. Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev 2007; 13: 221–227.
- 2Presson AP, Partyka G, Jensen KM et al. Current estimate of Down syndrome population prevalence in the United States. J Pediatr 2013; 163: 1163–1168.
- 3Santamaria LB, Di Paola C, Mafrica F et al. Preanesthetic evaluation and assessment of children with Down's syndrome. ScientificWorldJournal 2007; 7: 242–251.
- 4Haché M, Sun LS. Perioperative management of patients with Down syndrome. Curr Pediatr Rev 2009; 5: 180–183.
10.2174/157339609789007196 Google Scholar
- 5Borland LM, Colligan J, Brandom BW. Frequency of anesthesia-related complications in children with Down syndrome under general anesthesia for noncardiac procedures. Pediatr Anesth 2004; 14: 733–738.
- 6 Special Olympics Bulletin: participation by Individuals with Down Syndrome Who Suffer from Atlantoaxial Dislocation Condition. Washington, DC. Special Olympics Bulletin, 1983.
- 7Hata T, Todd MM. Cervical spine considerations when anesthetizing patients with Down syndrome. Anesthesiology 2005; 102: 680–685.
- 8Tassone JC, Duey-Holtz A. Spine concerns in the special Olympian with Down syndrome. Sports Med Arthrosc 2008; 16: 55–60.
- 9Hankinson TC, Anderson RCE. Craniovertebral junction abnormalities in Down syndrome. Neurosurgery 2010; 66(Suppl. 3): A32–A38.
- 10Pueschel SM, Findley TW, Furia J et al. Atlantoaxial instability in Down syndrome: roentgenographic, neurologic, and somatosensory evoked potential studies. J Pediatr 1987; 110: 515–521.
- 11Birrer RB. The special olympics athlete: evaluation and clearance for participation. Clin Pediatr 2004; 43: 777–782.
- 12Trumble ER, Myseros JS, Smoker WRK et al. Atlantooccipital subluxation in a neonate with Down's syndrome. Case report and review of the literature. Pediatr Neurosurg 1994; 21: 55–58.
- 13Morton RE, Ali Khan M, Murray-Leslie C et al. Atlantoaxial instability in Down's syndrome: a five year follow up study. Arch Dis Child 1995; 72: 115–119.
- 14Cremers MJG, Ramos L, Bol E et al. Radiological assessment of the atlantoaxial distance in Down's syndrome. Arch Dis Child 1993; 69: 347–350.
- 15Cohen WI. Current dilemmas in Down syndrome clinical care: Celiac disease, thyroid disorders, and atlanto-axial instability. Am J Med Genet C: Semin Med Genet 2006; 142: 141–148.
- 16Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics 2011; 128: 393–406.
- 17Litman RS, Zerngast BA, Perkins FM. Preoperative evaluation of the cervical spine in children with trisomy-21: results of a questionnaire study. Paediatr Anaesth 1995; 5: 355–361.
- 18Freeman SB, Bean LH, Allen EG et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med 2008; 10: 173–180.
- 19Weijerman ME, Van Furth AM, Van Der Mooren MD et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 2010; 169: 1195–1199.
- 20Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum, management and survival over 22 years. Arch Dis Child 2012; 97: 326–330.
- 21Frid C, Drott P, Lundell B et al. Mortality in Down's syndrome in relation to congenital malformations. J Intellect Disabil Res 1999; 43: 234–241.
- 22Paladini D, Tartaglione A, Agangi A et al. The association between congenital heart disease and Down syndrome in prenatal life. Ultrasound Obstet Gynecol 2000; 15: 104–108.
- 23Lacour-Gayet F, Clarke D, Jacobs J et al. The Aristotle score: a complexity-adjusted method to evaluate surgical results. Eur J Cardiothorac Surg 2004; 25: 911–924.
- 24Jenkins KJ, Gauvreau K, Newburger JW et al. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg 2002; 123: 110–118.
- 25Baltimore RS, Gewitz M, Baddour LM et al. Infective endocarditis in childhood: 2015 update. A scientific statement from the American Heart Association. Circulation 2015; 132: 1487–1515.
- 26Bai W, Voepel-Lewis T, Malviya S. Hemodynamic changes in children with Down syndrome during and following inhalation induction of anesthesia with sevoflurane. J Clin Anesth 2010; 22: 592–597.
- 27Tulloh RMR. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005; 6: 174–180.
- 28King P, Tulloh R. Management of pulmonary hypertension and Down syndrome. Int J Clin Pract 2011; 65(Suppl. 174): 8–13.
- 29Carmosino MJ, Friesen RH, Doran A et al. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg 2007; 104: 521–527.
- 30Chi TPL, Krovetz LJ. The pulmonary vascular bed in children with Down syndrome. J Pediatr 1975; 86: 533–538.
- 31Sharma M, Khera S, Sondhi V et al. A study to determine the prevalence of pulmonary arterial hypertension in children with Down syndrome and congenital heart disease. Med J Armed Forces India 2013; 69: 241–245.
- 32Soudon P, Stijns M, Tremouroux Wattiez M et al. Precocity of pulmonary vascular obstruction in Down's syndrome. Eur J Cardiol 1975; 2: 473–476.
- 33McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. J Pediatr 2011; 158: 319–325.
- 34Shah PS, Hellmann J, Adatia I. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med 2004; 32: 168–170.
- 35Cua CL, Blankenship A, North AL et al. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007; 28: 250–254.
- 36Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. N Engl J Med 1982; 307: 1170–1173.
- 37Cooney TP, Wentworth PJ, Thurlbeck WM. Diminished radial count is found only postnatally in Down's syndrome. Pediatr Pulmonol 1988; 5: 204–209.
- 38Schloo BL, Vawter GF, Reid LM. Down syndrome: patterns of disturbed lung growth. Hum Pathol 1991; 22: 919–923.
- 39Jacobs JN, Gray RF, Todd NW. Upper airway obstruction in children with Down syndrome. Arch Otolaryngol Head Neck Surg 1996; 122: 945–950.
- 40Pandit C, Fitzgerald DA. Respiratory problems in children with Down syndrome. J Paediatr Child Health 2012; 48: E147–E152.
- 41Shott SR. Down syndrome: analysis of airway size and a guide for appropriate intubation. Laryngoscope 2000; 110: 585–592.
- 42Lam DJ, Jensen CC, Mueller BA et al. Pediatric sleep apnea and craniofacial anomalies: a population-based case-control study. Laryngoscope 2010; 120: 2098–2105.
- 43Ng DK, Hui HN, Chan CH et al. Obstructive sleep apnoea in children with Down syndrome. Singapore Med J 2006; 47: 774–779.
- 44Banjar HH, Jamil M, Kattan H et al. Sleep study abnormalities in patients with Down syndrome. Curr Pediatr Res 2013; 17: 49–54.
- 45Henry E, Walker D, Wiedmeier SE et al. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A 2007; 143: 42–50.
- 46Smith OP. Haematological disorders in Down syndrome. Paediatr Child Health 2013; 23: 497–500.
10.1016/j.paed.2013.02.007 Google Scholar
- 47Zipursky A, Brown E, Christensen H et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997; 21: 97–101.
- 48Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20.
- 49Frid C, Drott P, Otterblad Olausson P et al. Maternal and neonatal factors and mortality in children with Down syndrome born in 1973–1980 and 1995–1998. Acta Paediatr 2004; 93: 106–112.
- 50Rasmussen SA, Wong L, Correa A et al. Survival in infants with Down syndrome, Metropolitan Atlanta, 1979–1998. J Pediatr 2006; 148: 806–812.e1.
- 51 The Professional Advisory Committee, National Down Syndrome Congress. Megavitamin Therapy. 2010; Available at: www.ndsccenter.org/about-ndsc/position-statements/. Accessed 15 May, 2014.
- 52 Down Syndrome – A Metabolic Deficiency. 2014; Available at: http://www.warnerhouse.com/trisomy.htm. Accessed 20 May, 2014.
- 53Moriau M, Crasborn L, Lavenne-Pardonge E et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Drug Res 1993; 43: 110–118.
- 54 Nutrivene-D Powder – New Formula 2014 Nutritional Profile. 2014; Available at: https://www.nutivene.com/dynamic_pages/NTVPOWDERPROF0114Rev.pdf. Accessed 15 May, 2014.
- 55 The Professional Advisory Committee, National Down Syndrome Congress. Piracetam; Available at: www.ndsccenter.org/issue-position-statements/. Accessed 23 December 2015.
- 56 National Down Syndrome Society. Alternative Therapies. Available at: http://www.ndss.org/Resources/Therapies-Development/Alternative-Therapies/. Accessed 8 May, 2014.